Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SC-006 +/- budigalimab in advanced colorectal cancer
NCT03035279Phase 1Terminated
- Sponsor
- AbbVie Inc.
- Start
- Mar 2017
- Primary completion
- Mar 2019
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of SC-006 in colorectal cancer (CRC) (3 arms), sponsored by AbbVie Inc. Primary endpoint: Dose-Limiting Toxicities at 21 days. Started Mar 2017; status: terminated.
02
Drugs
SC-006
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03035279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03035279.